Drugs /

egfr inhibitor

Back to Drugs List

Overview

NCI Definition [1]:
Any tyrosine kinase inhibitor that targets the activity of the epidermal growth factor receptor (EGFR) tyrosine kinase. Inhibition of epidermal growth factor receptor tyrosine kinase may inhibit the growth of epidermal-lineage tumor cells, especially those that overexpress epidermal growth factor receptor.

Clinical Trials

View Clinical Trials for egfr inhibitor

Egfr inhibitor has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating egfr inhibitor, 1 is phase 2 (1 open).

Drug Details

Synonyms [2]:
epidermal growth factor receptor inhibitors, epidermal growth factor receptor inhibitor, egfr-tk inhibitor, egfr tyrosine kinase inhibitors, egfr tyrosine kinase inhibitor, egfr blocker
Drug Target(s) [2]:
EGFR
NCIT ID [1]:
C2167
SNOMED ID [1]:
C-781CF

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.